News coverage about Cellular Biomedicine Group (NASDAQ:CBMG) has been trending somewhat positive recently, according to Accern Sentiment. The research firm identifies positive and negative press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Cellular Biomedicine Group earned a media sentiment score of 0.22 on Accern’s scale. Accern also gave headlines about the biotechnology company an impact score of 45.2749830384952 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Here are some of the headlines that may have effected Accern Sentiment’s analysis:
- B. Riley Weighs in on Cellular Biomedicine Group Inc’s Q1 2018 Earnings (CBMG) (americanbankingnews.com)
- Cellular Biomedicine Group (CBMG) Earns Buy Rating from Analysts at B. Riley (americanbankingnews.com)
- Zacks: Cellular Biomedicine Group Inc (CBMG) Given Consensus Rating of “Hold” by Brokerages (americanbankingnews.com)
- Cellular Biomedicine Group (CBMG) Releases Earnings Results, Misses Expectations By $0.08 EPS (americanbankingnews.com)
- BRIEF-Cellular Biomedicine Group Reports Full-Year 2017 Financial Results And Recent Operational Progress (reuters.com)
Shares of Cellular Biomedicine Group (NASDAQ:CBMG) opened at $19.75 on Wednesday. The stock has a market cap of $338.38, a PE ratio of -11.16 and a beta of 3.71. Cellular Biomedicine Group has a twelve month low of $5.05 and a twelve month high of $22.75.
CBMG has been the topic of a number of research reports. B. Riley initiated coverage on shares of Cellular Biomedicine Group in a research note on Thursday, March 8th. They issued a “buy” rating and a $32.00 price target on the stock. BidaskClub upgraded shares of Cellular Biomedicine Group from a “hold” rating to a “buy” rating in a research note on Wednesday, January 10th. Finally, Maxim Group reiterated a “hold” rating on shares of Cellular Biomedicine Group in a research note on Tuesday, March 6th.
In other Cellular Biomedicine Group news, insider Yihong Yao acquired 4,167 shares of the business’s stock in a transaction on Friday, December 22nd. The stock was purchased at an average price of $12.00 per share, with a total value of $50,004.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Tony Liu acquired 29,167 shares of the business’s stock in a transaction on Friday, December 22nd. The stock was acquired at an average cost of $12.00 per share, with a total value of $350,004.00. The disclosure for this purchase can be found here. Insiders acquired a total of 41,667 shares of company stock valued at $500,004 in the last three months. Insiders own 8.20% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This news story was reported by BBNS and is the property of of BBNS. If you are reading this news story on another publication, it was illegally stolen and republished in violation of United States & international copyright & trademark law. The correct version of this news story can be viewed at https://baseballnewssource.com/2018/03/14/somewhat-positive-news-coverage-somewhat-unlikely-to-affect-cellular-biomedicine-group-cbmg-stock-price-2/2028367.html.
Cellular Biomedicine Group Company Profile
Cellular Biomedicine Group Inc is a United States-based company which is engaged in the development of cell therapy technologies. The Company develops proprietary cell therapies for the treatment of cancer and degenerative diseases. The Company conducts immuno-oncology and stem cell clinical trials in China using products from the good manufacturing practices (GMP) laboratory.
Receive News & Ratings for Cellular Biomedicine Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellular Biomedicine Group and related companies with MarketBeat.com's FREE daily email newsletter.